Aberdeen Group
DNLI icon

Aberdeen Group’s Denali Therapeutics DNLI Stock Holding History

Aberdeen Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6M Sell
1,345,481
-508,965
-27% -$10.5M 0.05% 298
2026
Q1 		$35.6M Sell
1,854,446
-178,521
-9% -$3.55M 0.06% 281
2025
Q4 		$33.6M Buy
2,032,967
+919,381
+83% +$15.5M 0.05% 294
2025
Q3 		$16.2M Buy
1,113,586
+210,835
+23% +$3.03M 0.03% 499
2025
Q2 		$12.6M Buy
902,751
+142,936
+19% +$2.01M 0.02% 544
2025
Q1 		$10.3M Buy
759,815
+357,533
+89% +$6.85M 0.02% 559
2024
Q4 		$8.2M Buy
402,282
+38,603
+11% +$988K 0.02% 546
2024
Q3 		$10.6M Sell
363,679
-209,356
-37% -$5.19M 0.02% 511
2024
Q2 		$13.3M Buy
573,035
+57,016
+11% +$1.09M 0.03% 461
2024
Q1 		$10.6M Buy
516,019
+191,190
+59% +$3.59M 0.02% 539
2023
Q4 		$6.97M Buy
+324,829
New +$6.43M 0.02% 617

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's DNLI Position: Q2 2026 in Review

Aberdeen Group reduced its Denali Therapeutics (DNLI) stake by 27% in Q2 2026, selling an estimated $10.5M and leaving 1,345,481 shares worth $34.6M. The position accounts for 0.05% of the portfolio, ranked #298.

Aberdeen Group first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. The position peaked at $35.6M in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Aberdeen Group held 1,345,481 shares of Denali Therapeutics worth $34.6M as of Q2 2026.
  • Aberdeen Group sold 508,965 Denali Therapeutics shares in Q2 2026, an estimated $10.5M.
  • Denali Therapeutics made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #298 holding.
  • Aberdeen Group first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Aberdeen Group's Denali Therapeutics position peaked at $35.6M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.